Skip to main content
. 2024 Jun 6;45(27):2362–2376. doi: 10.1093/eurheartj/ehae324

Table 2.

Benefit/risk ratio in contemporary randomized controlled trials of antithrombotic therapy for primary and secondary prevention

Trial NNT NNH NNH/NNT
ASCEND60 91 112 1.2
COMPASS62 77 83 1.1
PEGASUS-TIMI 5463 79 81 1.0
THEMIS64 138 93 0.7

NNT, number needed to treat; NNH, number needed to harm.